Michael Ge

  • Citations Per Year
Learn More
In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculature, making it a promising strategy. To(More)
The involvement of presynaptic autoinhibition of Met-enkephalin release in naloxone-induced analgesia was studied. In both acetic acid writhing and tail-flick tests in mice, naloxone produced biphasic effects, analgesia at very low doses (1 microgram/kg s.c. or 1 ng intracisternal) and hyperalgesia at higher doses (100 micrograms/kg s.c. or 100 ng(More)
Bicuculline methiodide, a GABAA antagonist produced potent analgesia in the tail pinch test when it was given intracisternally (i.c.) but not intrathecally (i.t.). The ED50 was 5 ng/mouse. This analgesia was antagonized by i.c. muscimol, a GABAA agonist. On the contrary, muscimol (i.t.) produced bicuculline-reversible analgesia. These findings suggest that(More)
The novel neuropeptide, neo-kyotorphin, produced a naloxone-resistant analgesia in the tail pinch test when given (IC) to mice. Pretreatments with implantation of a morphine pellet or with phentolamine (10 micrograms IT) or with reserpine (10 mg/kg SC) did not attenuate this analgesia, yet the analgesia was antagonized by GABA mimetics, such as muscimol(More)
In vivo release of endogenous gamma-aminobutyric acid (GABA) and glutamic acid into the 4th ventricle of the rat brain in response to noxious stimuli was examined. Both these compounds were dansylated and the concentrations determined, using high-performance liquid chromatography (HPLC) combined with an UV detector. Following noxious stimuli (subcutaneous(More)
Opioid kappa-agonists had much more potent inhibitory effects on the high K+-evoked Met-enkephalin release from rat brain slices than did the mu- or delta-agonists. The opioid kappa- antagonist, MR2266 enhanced the evoked release of Met-enkephalin to a greater extent than did mu- or delta-antagonists in vitro and had a potent analgesia in mice in vivo.(More)
  • 1